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Abstract
Background: With the advent of affordable and comprehensive sequencing technologies, access to molecular
genetics for clinical diagnostics and research applications is increasing. However, variant interpretation remains
challenging, and tools that close the gap between data generation and data interpretation are urgently required. Here
we present a transferable approach to help address the limitations in variant annotation.
Methods: We develop a network of Bayesian logistic regression models that integrate multiple lines of evidence to
evaluate the probability that a rare variant is the cause of an individual’s disease. We present models for genes causing
inherited cardiac conditions, though the framework is transferable to other genes and syndromes.
Results: Our models report a probability of pathogenicity, rather than a categorisation into pathogenic or benign,
which captures the inherent uncertainty of the prediction. We find that gene- and syndrome-specific models
outperform genome-wide approaches, and that the integration of multiple lines of evidence performs better than
individual predictors. The models are adaptable to incorporate new lines of evidence, and results can be combined
with familial segregation data in a transparent and quantitative manner to further enhance predictions.
Though the probability scale is continuous, and innately interpretable, performance summaries based on thresholds
are useful for comparisons. Using a threshold probability of pathogenicity of 0.9, we obtain a positive predictive value
of 0.999 and sensitivity of 0.76 for the classification of variants known to cause long QT syndrome over the three most
important genes, which represents sufficient accuracy to inform clinical decision-making. A web tool APPRAISE
[http://www.cardiodb.org/APPRAISE] provides access to these models and predictions.
Conclusions: Our Bayesian framework provides a transparent, flexible and robust framework for the analysis and
interpretation of rare genetic variants. Models tailored to specific genes outperform genome-wide approaches, and
can be sufficiently accurate to inform clinical decision-making.
Background
With ongoing technology developments, DNA sequenc-
ing is becoming increasingly feasible for a range of clinical
conditions [1-4]. However, many healthy individuals carry
rare variants in disease-associated genes, and our ability
to interpret novel genetic findings struggles to keep pace
with our ability to generate genetic data [5-8]. Thus, dis-
tinguishing genetic variants that cause disease from rare
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but benign variants is one of the principal challenges in
contemporary clinical genetics.
To determine whether a novel variant found in a patient
is likely to be pathogenic, well-powered segregation anal-
ysis or functional biochemical characterisation could be
performed [9,10]. These are often impractical due to cost
and time constraints, or a lack of phenotypically charac-
terised family members for segregation studies. An alter-
native is to integrate evidence from various sources to
make accurate predictions about the consequences of the
observed variant, using approaches such as decision trees
or more informal guidelines [9-12].
© 2015 Ruklisa et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ruklisa et al. GenomeMedicine  (2015) 7:5 Page 2 of 16
Here we develop a robust and transparent approach to
predicting whether or not a novel protein-altering vari-
ant is the principal cause of a patient’s cardiac disease.
We consider long QT syndrome (LQTS [MIM 192500]),
Brugada syndrome (BrS [MIM 601144]) and hypertrophic
cardiomyopathy (HCM [MIM 192600]). Our approach
integrates sources of evidence including allele frequency,
amino acid conservation, predictors based on physic-
ochemical properties, and gene- and domain-specific
effects, with odds ratios associated with each source of
evidence estimated from training data specific to each
syndrome. We specify syndrome- and gene-specific mod-
els because we expect them to be more accurate than
genome-wide tools, as has been shown previously [12,13].
Differences in parameter values across genes or domains
may be driven, for example, by whether the mechanism of
pathogenesis involves gain or loss of function.
We require our framework to be transparent in its
assumptions, expandable to include new kinds of evi-
dence, and to report a probability of pathogenicity,
rather than simply classifying the variant as benign or
pathogenic for a syndrome. These requirements are met
using Bayesian inference, in which the posterior odds of
pathogenicity is computed as:
Posterior odds = Prior odds × Likelihood ratio (1)
Recall that odds is related to probability (P) via Odds =
P/(1 − P), and that the likelihood ratio (LR) is given by:
LR = Probability of observing theevidence if the variant is pathogenicProbability of observing the evidence if the variant is benign
(2)
A simple approach to integrating multiple sources
of evidence, called naïve Bayes, sequentially applies
Equation (1) for each piece of evidence, therefore assum-
ing independence [14]. This often works well when the
predictor variables are not too correlated, but our predic-
tors are often highly correlated and so joint modelling of
all available predictor variables is required.
Bayesian frameworks have been previously used to inte-
grate evidence for the interpretation of genetic variation,
particularly in the assessment of variants that may cause
familial cancer syndromes (discussed in [10,15]). Here,
naïve Bayesian frameworks have been applied to com-
bine sources of evidence for variant pathogenicity [16,17],
and also to account for experimental variability in an in
vitro assay used to validate BRCA1 variant effects [18].
Recently Campbell et al. employed a similar framework
to prioritise genes coincident with copy number vari-
ants for a likely role in the pathogenesis of epilepsy [19].
Here the authors were classifying genes, not variants,
but there are parallels with the challenge we address.
They derived empirical likelihood ratios for a number of
predictors, then normalised and averaged them to yield
a composite metric. Though the integration of individual
predictors into the composite metric was not Bayesian,
an explicit Bayesian framework was subsequently invoked
to combine this pathogenicity score with information on
background population rates of genetic variation in each
gene. We use equivalent frequency data in our model
to derive gene-level prior probabilities, which will be
modified according to variant-level evidence to produce
variant-specific predictions.
We also move from a naïve Bayesian approach to the
development of a network of Bayesian logistic regres-
sion models, in which the probability that a variant is
pathogenic is modelled in terms of a linear combination of
predictor variables. For each syndrome, we develop a dis-
tinct linear predictor for each of three categories of coding
variants: missense substitutions, inframe indels (inser-
tions and deletions) and radical variants (nonsense substi-
tutions, disruptors of consensus splice sites and frameshift
indels). To fit the models, we use training sets of variants
in known cardiac disease genes, which are identified as
pathogenic or benign according to a rigorous definition
detailed below.
Methods
Ethical approval was not required, as this study employed
reanalyses of published data in the public domain.
For each syndrome (LQTS, BrS and HCM), we identi-
fied a set of genes known to harbour pathogenic variants
for that syndrome and, for each gene, derived prior odds
that a rare variant is pathogenic. Next, we identified rel-
evant predictors and used them to construct Bayesian
logistic regression models, trained using a set of well-
characterised rare variants. We now describe these steps
in more detail.
Prior odds of pathogenicity
The probability that an observed variant is pathogenic
depends on the gene in which it is located and the syn-
drome of the patient. In a patient with LQTS for exam-
ple, a variant in KCNQ1 (a gene implicated in a large
proportion of LQTS cases) has a higher probability of
pathogenicity than a variant in KCNJ5 (which has only
been implicated in a handful of cases). Similarly, prior
evidence indicates that a variant in the gene MYH7 has
a substantial probability to be pathogenic in an HCM
patient, but a low probability of pathogenicity for LQTS.
The prior odds of pathogenicity for a rare variant in gene
G, found in an affected individual, might be assumed to
be:
Prior odds of pathogenicity = Burden of pathogenic variants in casesBurden of benign rare variants in cases
(3)
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where burden means the proportion of individuals who
have a variant in G of the type stated. Because the
pathogenic/benign status of variants is often not known
with certainty, we cannot directly estimate either the
numerator or denominator of Equation (3). However, it
is reasonable to assume that the burden of benign rare
variants in cases is equal to the burden of rare variants
in controls, which we estimate from population sequence
data generated by the Exome Sequencing Project [20]
(Table 1). Therefore, we could replace the right-hand side
of Equation (3) with:
Burden of rare variants in cases − Burden of rare variants in controls
Burden of rare variants in controls
(4)
The burden of rare variants in cases is estimated pri-
marily from literature reports of the yields of diagnostic
Table 1 Estimated burden of rare variants in cases and controls, for the calculation of prior odds of pathogenicity
Non-radical variants Radical variants
Gene Syndrome Burden in Burden in Prior Burden in Burden in Prior Case burden in literature
case series controls odds case series controls odds (combined radical and
non-radical variants)
KCNQ1 LQTS 0.1784 0.0039 45 0.0384 0.0002 191 0.421
KCNH2 LQTS 0.1256 0.0048 25 0.0392 0 195 0.388
SCN5A LQTS 0.0584 0.0112 4 0.0028 0.0002 13 0.090
KCNE1 LQTS 0.0124 0.0014 8 0.0020 0 9 0.010
KCNE2 LQTS 0.0052 0.0011 4 0.0004 0.0002 1 0.010
KCNJ2 LQTS 0.0026 0.92 0 0.2 0.010
ANK2 LQTS 0.0386 0.2 0 0.2 0.010
CACNA1C LQTS 0.0112 0.2 0 0.2 0.010
CAV3 LQTS 0.0011 4 0.0002 0.2 0.010
SCN4B LQTS 0.0017 0.2 0.0006 0.2 0.001
AKAP9 LQTS 0.0393 0.2 0.0005 0.2 0.001
SNTA1 LQTS 0.0043 0.2 0.0003 0.2 0.001
KCNJ5 LQTS 0.0045 0.2 0 0.2 0.001
MYBPC3 HCM 37.5 37.5 0.375
MYH7 HCM 25 25 0.250
TNNT2 HCM 6 6 0.060
TNNI3 HCM 6 6 0.060
SCN5A BrS 30 30 0.300
CACNA1C BrS 1 1 0.010
CACNA2D1 BrS 1 1 0.010
CACNB2 BrS 1 1 0.010
GPD1L BrS 1 1 0.010
KCND3 BrS 1 1 0.010
KCNE3 BrS 1 1 0.010
SCN1B BrS 1 1 0.010
SCN3B BrS 1 1 0.010
The estimated burden of rare variants in genes for LQTS, HCM and BrS in cases and ESP controls, where rare corresponds to an allele frequency<0.0005. Burdens are
given as proportions (range 0-1). Values are presented for radical (truncating) variants and for inframe indels and missense substitutions combined (non-radical
variants). For all genes, an estimate of the burden in cases is derived from the literature. For five LQTS genes, the burden in cases is estimated both from literature
reports and from a prospective case series; the latter are used in our model where available. Otherwise half the literature-based estimate is used for LQTS genes (see
text for discussion). Zero values of control frequencies are replaced by 0.0002 to compute ratios. For HCM and BrS the burden in cases is taken from the literature, and
the burden in controls is fixed at 0.01.
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genetic testing for each gene and syndrome [21-24], as
detailed in Additional file 1: Table S4 and summarised in
Table 1.
In practice (Table 1), we made some adjustments to
Equation (4). If any estimated burden of rare variants in
the controls was zero, it was replaced by the minimum
non-zero frequency (0.0002). This was done under the
assumption that the minimum frequency observed corre-
sponds to a variant count of 1. An alternative approach
would be to transform frequencies with (x + 1)/n where
x is the count of variants and n is the number of indi-
viduals considered, but this information is not uniformly
available. When the prior odds obtained from Equation
(4) were smaller than 0.2, they were replaced by 0.2. Such
a truncation was performed because estimation of the
burden of rare variants in cases gets less precise in the
lower range of values, and random fluctuations in esti-
mated control frequencies have more impact upon the
prior odds within this range of rare variant frequencies
in cases. The threshold for truncation of prior odds was
set to 0.2, following simulation experiments demonstrat-
ing that predictions were equally accurate when the prior
odds were set at either 1 or 0.2.
We employed an alternative approach to calculating
prior odds for five LQTS genes (KCNQ1,KCNH2, SCN5A,
KCNE1 and KCNE2) that is not based on the literature
reports given in Additional file 1: Table S4. We obtained
independent burden estimates from a published prospec-
tive case series [25] comprising 2,500 unrelated cases
referred for LQTS clinical genetic testing.
For the five LQTS genes with case series data, Table 1
shows that the two approaches yield different estimates, as
the burden of pathogenic variants in individuals referred
for LQTS genetic testing in the clinical case series (30%)
was lower than that typically reported in research studies
(70% to 75%) [21,22]. It is likely that clinicians employ dif-
ferent thresholds for defining cases in a research setting or
subspecialist clinical centre than are employed for day-to-
day referrals to a clinical genetic diagnostics service. For
better performance in the latter, more challenging, set-
ting, we based our rare variant burden estimates on the
case series. Given that these estimates were on average
about half those predicted from the literature when both
estimates were available, we reduced by a factor of two
the prior odds derived from literature-based estimates for
the other eight LQTS genes (ANK2, KCNJ2, CACNA1C,
CAV3, SCN4B, AKAP9, SNTA1 and KCNJ5).
Prior odds for HCM- and BrS-related genes were esti-
mated using only information from the literature, in the
absence of additional prospective case series for these syn-
dromes, as summarised in Table 1. Combining literature-
derived case burdens with population-derived estimates
of control burdens led to unstable estimates of model
parameters, due to the small numbers of variants. To avoid
widely fluctuating priors (with very low confidence), we
used an average estimated benign rare variant burden of
1% for these genes, yielding conservative priors.
Predictors of pathogenicity
Having established prior odds for individual genes for
each syndrome, we next consider sources of evidence
that can be used to obtain the posterior probability of
pathogenicity for an observed variant. First we describe
the training data, comprising rare variants of known
pathogenic/benign status, which will be used to estimate
model parameters.
Training data
We generated a compendium of previously reported
sequence variants in our genes of interest from HGMD
professional version 2011.4, UniProt, dbSNP 135 and pub-
lished case series [5,12,25]. From these we selected a
subset of variants that could be robustly categorised as
benign or pathogenic, assessed separately for each syn-
drome (LQTS, BrS and HCM). Variants were defined
as pathogenic if they were reported as causing disease
with supporting evidence of a functional effect in vitro
and/or mechanistic information. Variants were defined as
benign if identified in prospectively ascertained cohorts
of healthy individuals [25], or if present in any dbSNP
population with a frequency >0.01. Variants not satisfy-
ing either of these criteria, and hence assessed to have
intermediate probability of pathogenicity, were removed.
In total, 320 variants were retained in the LQTS train-
ing set (164 pathogenic and 156 benign), 73 variants in
the BrS set (17 pathogenic and 56 benign), and 95 vari-
ants in HCM-related genes (67 pathogenic and 28 benign).
These comprised 428 missense variants, 41 radical and
19 inframe indels. Variants are shown in Tables S1,S2,S3
(Additional file 1).
For HCM genes, we also used a second, indepen-
dently ascertained training set. Pathogenic variants were
taken from the training set previously applied to the
PolyPhen-HCM classifier [12], supplemented with further
pathogenic variants manually curated to the same robust
criteria, and additional benign variants identified in a
well-phenotyped control cohort [6]. These sources yielded
18 pathogenic and 39 benign substitution variants.
Protein domains
The pathogenicity of a coding variant depends on its loca-
tion within the protein. Clustering of rare coding variants
in hotspots has been described for a number of pro-
teins [26]. This may simply represent high local mutability
and/or lack of constraint, if variants cluster in both cases
and controls. Alternatively, the region may be intoler-
ant of variation, and an increase in the proportion of
variants that are pathogenic may be informative for the
interpretation of subsequent variants [5,16].
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Therefore, we included domain-specific terms, with
uninformative prior distributions, in the linear predictors
for inframe and missense variants. Each domain effect
is assumed to be normally distributed, with mean zero
and variance an inverse-gamma random variable. For each
gene, protein domain annotations were obtained from
Uniprot [27] using the ‘Regions’ fields of the Sequence
Annotation section. We explored informative prior distri-
butions for domain terms; for example, estimates of the
probability of pathogenicity of variants found in distinct
domains of KCNQ1, KCNH2 and SCN5A in [5] were con-
sidered. However, informative priors did not improve pre-
dictions, probably because these correlated with domain
effects estimated de novo from our LQTS training data,
which included many of the variants used by Kapa et al.
to derive their estimates. No domain term is included for
the prediction of variants in genes KCNJ2, CAV3, SCN4B,
AKAP9, SNTA1, KCNJ5, CACNA2D1, CACNB2, GPD1L,
SCN1B, MYBPC3 and TNNT2, because domains of these
genes are not sufficiently represented in our LQTS, BrS
and HCM training data.
Allele frequencies in controls
Rare monogenic diseases cannot be attributed to variants
that are common, though such variants may contribute to
the risk of common complex diseases, or act as modifiers
of rare disease. However, pathogenic variants may exist
at a low frequency in populations of ostensibly healthy
controls, as these may be in a pre-clinical disease phase,
or phenotyped using methods with incomplete sensitivity.
We explored the use of variant frequency as a quantita-
tive predictor, but found that the best performance was
obtained using a binary indicator of whether the vari-
ant has been recorded in a control database. As control
sets improve over time, this decision may need to be
revisited.
Control data sets were taken from the 1000 Genomes
project and the Exome Sequencing Project [20,28]. The
1000 Genomes frequency was obtained from phase 1
of the project (2,184 haploid exomes) and comprised
data from 14 distinct populations including European
(five), African (three), East Asian (three) and Latin
American (three) populations. The Exome Sequencing
Project frequency was derived from approximately 13,000
haploid exomes from European-Americans and African-
Americans in a 2:1 ratio. Published variants from a further
control cohort of seemingly healthy controls and volun-
teers [5] comprising 1,300 individuals (47% Caucasian,
26% African American, 11% Hispanic, 10% Asian and 6%
unknown/other), were used for the three major LQTS
genes (KCNQ1,KCNH2 and SCN5A). For our LQTS train-
ing data, 40% of the benign variants had a non-zero
frequency in the controls, in contrast to 2% of pathogenic
variants (typically only one occurrence).
Conservation
Where a protein residue is conserved across a wide range
of species, this is widely interpreted as evidence that
the residue is functionally important and hence intoler-
ant of variation. We used protein sequence alignments
of Ensembl-defined one-to-one orthologues for up to 70
species, and for each variant we recorded the species in
which the corresponding residue was conserved. Due to
the variable quality in genome sequencing and the auto-
mated nature of the orthologue alignments, a residue was
deemed as conserved if it aligned with the same amino
acid and non-conserved if aligned with a different amino
acid; for residues aligning with gaps in the alignment or
X (indicating poor sequence quality), the data for that
species were disregarded. Residues were initially classified
into five non-overlapping categories indicating whether
they were conserved in all 70 species, all vertebrates,
(eutherian) mammals, primates or were not conserved.
During model fitting, this was simplified to three cate-
gories of conservation, encoded as two binary indicators
(conserved in primates and conserved in all species) with
not conserved as the reference state.
Non-synonymous single nucleotide polymorphism
algorithms
Several algorithms aim to predict the pathogenicity of
missense substitutions, largely based on physicochemi-
cal properties of the reference and alternate amino acids
and their sequence contexts. Three of these have been
incorporated as predictors in our model.
The Grantham score [29], first described in 1974, is
a measure of the physicochemical similarity of pairs of
amino acids. It is not dependent on sequence context.
Polymorphism phenotyping v2 (PolyPhen) aims to pre-
dict the impact of single amino acid substitutions using
sequence, phylogenetic and structural information [30].
It is available in two flavours, trained on different data
sets. HumDiv aims to identify alleles that may alter pro-
tein function, while HumVar aims to discriminate vari-
ants with large effects (sufficient to cause Mendelian
disease) from alleles that are at most only mildly delete-
rious. Our model uses the HumVar classifier. The sorting
intolerant from tolerant (SIFT) algorithm also predicts
whether an amino acid substitution affects protein func-
tion, based on the degree of conservation of amino acid
residues in sequence alignments derived from closely
related sequences [31]. Importantly, SIFT does not predict
whether an alteration in protein function will be sufficient
to cause disease.
The distributions of Grantham, PolyPhen and SIFT
scores obtained for pathogenic and benign variants in the
LQTS training set are shown in Figure 1. The PolyPhen
and SIFT scores both lie between 0 and 1, but with
opposite polarities (higher PolyPhen scores and lower
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Figure 1 Comparison of the distributions of predictor variables for benign and pathogenic variants. Histograms depict the numbers of
variants that are pathogenic (magenta bars) and benign (black bars) with predictor values within a range as indicated on the x-axes for the four
predictor variables. Conservation categories are defined in the Methods section.
SIFT scores both indicate greater risk of pathogenicity).
Grantham scores range up to 205 in the training set,
with higher values indicating greater risk of pathogenic-
ity. To facilitate interpretation of model coefficients in
our model, Grantham scores were rescaled to lie between
0 and 1 by dividing by 205, and SIFT was replaced by
1 − SIFT.
Constructing the Bayesian prediction model
Our Bayesian logistic regression model is represented
diagrammatically in Figure 2, and in BUGS format in
Additional file 2. For each variant, the logistic transform
of the probability for it to be pathogenic is calculated
as a sum over contributions from the predictor variables
described above. The contributions from quantitative pre-
dictors are either linear or quadratic.
Our model proposes interrelated linear predictors for
each of the three classes of variant, chosen because of
background information indicating different probabili-
ties of pathogenicity associated with each class. While
the majority of cases of inherited cardiac conditions are
caused by missense substitutions, there is also an appre-
ciable burden of rare missense variants in healthy controls
[5,25]. By contrast, radical variants are almost absent from
the general population, so that for many inherited cardiac
conditions such a variant in a patient is conventionally
considered pathogenic [5]. Inframe indels have previously
been classified as radical, because they are also rare in
healthy controls [5], but we have classified these separately
because of the evidence for different properties of this
class [25]. The likely effects of different variant classes also
depends on the molecular mechanism of disease. A mis-
sense variant may lead to either loss or gain of function,
whereas radical variants usually produce loss of function.
The probability of pathogenicity of radical variants should
depend on whether disease is mediated by loss or gain
of function of the gene of interest. Non-coding variants
and near splice site substitutions that do not disrupt the
consensus donor/acceptor sites are not considered in the
model.
The model for radical variants is the simplest, including
only two predictors (variant frequency indicator and gene
Ruklisa et al. GenomeMedicine  (2015) 7:5 Page 7 of 16
Figure 2 Graphical representation of the three prediction
models for a single syndrome. The logistic regression models are
represented as the three rectangles on the right, for a radical variant
(top), an inframe indel (middle) and a missense substitution (bottom).
Ellipses describe model predictors. Each model is additive on a logistic
scale. Multiple arrows emerging from an ellipse indicate that the
parameter is shared across the models indicated by the destinations
of the arrows. This diagram represents the model for one syndrome.
effect). The intercept represents the average pathogenicity
of radical variants (Figure 2) and it, like other intercept
parameters introduced below, is assigned a N(0, 10) prior
distribution. Domain terms are not included because the
fraction of radical variants that are pathogenic is simi-
lar across domains [5], and loss of function is expected
to be largely independent of the precise location of the
truncating variant. Conversely, gene effects are important
for the pathogenicity of radical variants due to the differ-
ences between genes in the effects of gain-of-function and
loss-of-function variants, among other factors.
The model for inframe indels is similar to that for rad-
ical variants, but also includes domain-specific terms.
Domain terms have normal prior distribution centred at
0 (its variance is estimated from the data and has an
inverse-gamma prior distribution). We use the same gene
effects as for missense variants. For interpretability of the
parameters, we also include the intercept that measures
average pathogenicity over all non-radical variants, and
we add to this the inframe effect term, whichmeasures any
excess pathogenic risk of inframe variants over missense
substitutions.
The richest model is for the missense substitutions,
which includes all the predictors mentioned above plus
Grantham, SIFT, PolyPhen and the two conservation
indicators, for primates and all species. For the three
quantitative predictor variables, we considered various
models in a series of simulation experiments and found
the best performance with SIFT modelled as a lin-
ear covariate, but Grantham and PolyPhen scores both
included as quadratic functions. The linear part of each
model is assigned a N(0, 10) prior distribution.
Our model uses several hyperparameters. One hyper-
parameter determines the standard deviation of a normal
prior. Two hyperparameters specify a gamma distribution
that models domain effects. We have tried experimentally
varying the values of these parameters. When we replaced
standard deviations of normal distributions by larger val-
ues, for example 100, we found that the fitted effect sizes
of predictors became large, leading to overfitting. In con-
trast, smaller standard deviations shrank the effect sizes
too much, thus preventing confident predictions for many
variants. The parameters of the gamma distribution had a
less noticeable effect on the results; in the end we chose
parameters that are consistent with our expectations of
the magnitude of domain effects and that prohibit overfit-
ting, which is a potential concern with nearly 60 domains
of LQTS genes.
Model fitting and assessment
All model parameters are fitted simultaneously over the
three variant classes to allow simultaneous estimation
from the training data set of the shared parameters indi-
cated by multiple arrows in Figure 2. Estimation for LQTS
and BrS models was also done jointly for combined esti-
mation of the shared parameters (variance of domain
effects, scale of gene priors, intercepts for all variant
classes and parameters modelling the effect of Grantham,
SIFT, PolyPhen and conservation). The HCM model was
fitted separately and also in combination with the LQTS
model (the shared parameters were a subset of those
shared for LQTS and BrS: variance of domain effects
and parameters modelling the effect of Grantham, SIFT,
PolyPhen and conservation).
The fitting was done by a Markov chain Monte Carlo
(MCMC) procedure within the JAGS software [32]. Ten
chains, each with 40,000 iterations, were simulated to
estimate the effect sizes. The first 20% of outputs were
discarded as burn-in. The convergence of simulations was
assessed by a potential scale reduction estimator [33]
applied to each parameter separately:
R = √Var(φ|y)/W
where
Var(φ|y) = W × (n − 1)/n + B × 1/n,
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while B is a variance in sampled parameter values between
ten chains, W is a variance in sampled parameter values
within a single chain and n = 32,000 is the number of non-
discarded simulations. We required R < 1.1 to terminate,
which was always satisfied after 40,000 iterations.
The post burn-in simulations were used to report
parameter medians, which were subsequently used as
fitted values in a prediction model for novel variants. Pos-
terior probability distributions for the model parameters
can be estimated from the MCMC output, which is use-
ful for model diagnosis. Goodness of fit for all models was
assessed via cross-validation. We randomly split the data
set 100 times into training and test sets such that each test
set had 1/10 of pathogenic and 1/10 of benign variants.We
fitted the model (Figure 2) to each training set and then
calculated the pathogenic risk for the test variants.
Although the model outputs a posterior probability
of pathogenicity that is continuous and innately inter-
pretable, we also assess model performance by applying
a threshold to probabilities of pathogenicity and calculat-
ing standard metrics including sensitivity, specificity and
positive predictive value (PPV). To ensure that the PPV
appropriately reflects the prevalence of variants in the
intended test population (rather than the proportion of
benign and pathogenic variants in the cross-validation test
set), we calculate PPV using the equation:
PPV = Prior odds × True positive rate(Prior odds × True positive rate) + False positive rate
(5)
where the prior odds are derived for each syndrome as
described above and summarised in Table 1. Recall that
the true positive rate is synonymous with sensitivity, and:
False positive rate = 1 − Specificity
A model description in BUGS format, a table of fit-
ted model coefficients, and scripts necessary to reproduce
these analyses are provided in Additional files 2, 3, 4.
Results
Models for long QT syndrome
The results for 100 cross-validation data sets show
that most of the pathogenic variants were assigned
high probabilities of pathogenicity: 73% of them are
assigned P(pathogenic) > 0.9, while 2.2% are assigned
P(pathogenic) < 0.1. Conversely 71% of benign variants
are assigned P(pathogenic) < 0.1, while only 0.6% are
assigned P(pathogenic) > 0.9.
Note that we are using P(pathogenic), the proba-
bility that a variant is pathogenic, as shorthand for
P(pathogenic|disease status + variant data), the probabil-
ity that a variant is pathogenic if it has certain character-
istics and given that it is found in an individual with an
appropriate disease phenotype.
Figure 3 depicts the receiver operating characteristic
(ROC) curves for this model, using predictions for 3,200
test variants from the 100 data splits, and Additional file 1:
Figure S2 shows alternative representations of model per-
formance. Ranking variants according to their probability
of pathogenicity, the top 84 places are taken by pathogenic
variants (53% of pathogenic variants). The PPV associ-
ated with a particular threshold for P(pathogenic) depends
on the prior odds. From Table 1, prior odds were 45 for
KCNQ1, 25 for KCNH2 and 4 for SCN5A, giving over-
all prior odds of 25 for these three genes. If we choose
a threshold of P(pathogenic) > 0.9, then the combined
PPV for KCNQ1, KCNH2 and SCN5A is 0.999. At this
threshold, 79% of pathogenic variants in KCNQ1, 82% of
KCNH2 and 39% of SCN5A were identified, with a com-
bined sensitivity of 76% across the three genes. For the
other genes that much more rarely cause LQTS, sensi-
tivity is lower (25%), but the PPV remains high (1). As
the training data are relatively sparse for these genes, pre-
dictions are appropriately cautious. Assessing across all
LQTS genes, the combined sensitivity is 73%, with PPV >
0.999. Performance metrics at other thresholds are shown
in Additional file 1: Figure S2 and Table S5.
The sensitivity of predictions can be different for the
three variant classes: 96% of pathogenic radical variants
are assigned P(pathogenic) > 0.9 while none of the
pathogenic inframe indels is assigned high probability
of pathogenicity. More cautious predictions for inframe
indels might be caused by the fact that most of the inframe
indels in the LQTS data set are benign. 71% of pathogenic
missense substitutions are assigned P(pathogenic) > 0.9.
Interestingly enough, the specificity is very high for mis-
sense substitutions: only 0.07% of benign variants are
assigned P(pathogenic) > 0.9. For three major LQTS
genes (KCNQ1, KCNH2 and SCN5A), sensitivities across
the three variant classes are as follows: 75% for mis-
sense variants, 96% for radical variants and 0% for inframe
indels. Similar sensitivities are obtained across all 13
genes. PPVs for the three major genes are 0.999 for mis-
sense variants, 1 for radical variants and 0 for inframe
indels.
Optimisingmodel predictors for long QT syndrome
We explored the choice of model predictors by compar-
ing nested submodels of the model shown in Figure 2, to
determine whether the model could be simplified without
loss of predictive accuracy. The models considered are:
• A full model as shown in Figure 2.
• A low-resolution domain model in which domain
annotations are simplified by merging domains to
yield a coarser description of the domain structure.
This involved merging the six transmembrane helical
domains and intervening extra- and intracellular
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Figure 3 Comparison of pathogenicity prediction models for LQTS. Receiver operating characteristic curves are shown for four nested LQTS
models, as well as for SIFT with and without the addition of prior odds. The inner plot shows the false positive rate from 0 to 0.1, while the axis of the
outer plot spans the false positive rate from 0 to 1. See text for explanation of the models. LQTS, long QT syndrome.
segments into transmembrane regions and looking at
the entire N- and C-termini regardless of specific
functional domains (PAS/PAC/cNBD in KCHN2 and
SAD in KCNQ1).
• A gene model, without domain effects.
• A genome-wide model with neither gene nor domain
effects.
For comparison against existing methods we also quan-
tified the performance of SIFT on the same data set, with
or without gene-specific priors:
• A prior odds and SIFT model contains only prior
odds of genes, SIFT effect and a separate intercept for
each variant class.
• A prior odds model distinguishes variant classes and
uses prior odds of genes.
• A SIFT model where SIFT is the only predictor apart
from a variant class.
The low-resolution domain model is consistently less
accurate than the full model (Figure 3). It appears that
including individual domains in the model is useful,
despite the fact that the data are sparse for some domains.
The gene model reaches a true positive rate of about 75%
for a false positive rate of 5%. It is inferior to the full
model at the small false positive rates that are of interest
in practice. The genome-wide model is similar to exist-
ing genome-wide pathogenic risk predictors. The results
obtained from this model are considerably worse than for
the gene model, indicating that the incorporation of prior
odds of pathogenicity for individual genes has a major
impact on predictive accuracy. The prior odds and SIFT
model occasionally outperforms the genome-wide model,
but is worse at small false positive rates. Both the prior
odds model and the SIFT model achieved 40% sensitiv-
ity at a 10% false positive rate. Neither of these predictors
on their own could make a model that would have suffi-
cient sensitivity and specificity; however, combining the
prior odds of individual genes and SIFT score noticeably
improved the predictive performance relative to either
alone.
Models for Brugada syndrome
The results in Figure 4 show that the sensitivity attained
by the initial full model is close to 65% at a false positive
rate of 10%, increasing to 75% at a false positive rate of
20%. Simpler models, excluding gene or domain effects,
were inferior as for LQTS, and are not shown. In the
magnified panel, the curve is nearly horizontal near the
origin (false positive rate 0 - 0.03) due to a few benign
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Figure 4 Pathogenicity predictionmodels for Brugada syndrome. The receiver operating characteristic curve for the full model for BrS is shown
alongside that for LQTS (as in Figure 3) for comparison. Sensitivity could be improved at low false positive rates by building a combined model, in
which some parameters were fit jointly for the LQTS and BrS models (see text for details) to compensate for the smaller BrS training set. Joint fitting
does not impede performance of the LQTS model. BrS, Brugada syndrome; LQTS, long QT syndrome.
variants having P(pathogenic) ≈ 1. A closer inspection
revealed that two missense variants had a high proba-
bility of pathogenicity due to a specific combination of
predictors: large PolyPhen probability, SIFT score close to
0, frequency absent and a moderate to large Grantham
score. Also one benign radical variant in SCN5A had
P(pathogenic) ≈ 1: there was no frequency data for it.
We compared the predictive performance of a full
model for BrS and a gene model for BrS that has no
domain effects. Both sensitivity and specificity were lower
for the gene model, and the differences between both
models were similar to the differences between equivalent
models for LQTS. In addition, we ran simulations for a
genome-wide model in the context of BrS: the predictions
yielded by a genome-wide model were less accurate than
those of the gene model and again the differences between
models were similar to those observed for LQTS.
We tried to enhance the predictions for BrS by com-
bining the training data set with the LQTS data set. We
postulated a new multivariate model with two outcomes
(pathogenic/benign for LQTS and pathogenic/benign for
BrS), which was then trained on the combined data. Gene
and domain effects were estimated separately for LQTS
and BrS, but the effects of SIFT, PolyPhen, Grantham,
conservation, frequency and inframe variants were esti-
mated jointly across the outcomes. Intercepts and scale
parameters for prior odds of genes were also shared across
the syndromes, as the small number of radical and inframe
variants in the BrS test set did not permit robust estima-
tion of these parameters. Each of the 100 cross-validation
test sets included 1/10 of the pathogenic variants and 1/10
of the benign variants for each of LQTS and BrS. The ROC
values were computed for each syndrome separately, using
only the test-set variants associated with that syndrome.
The combined model improved the BrS predictions
for false positive rates smaller than 5% (Figure 4 and
Additional file 1: Figure S2). The number of benign vari-
ants with high probabilities of pathogenicity has fallen,
despite there being few training variants in some BrS
genes. The separate (full) BrS model performs better at
false positive rates between 5% and 20%, which is of less
clinical usefulness. Under both models, the prediction
accuracy for BrS remains inferior to that of LQTS, because
of limited data. The performance for the LQTS variants
remained the same.
For SCN5A, the prior odds were 30 for BrS refer-
rals, and the PPV for the SCN5A gene at a threshold of
P(pathogenic) = 0.9 was 0.963 for the full model and
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0.998 for the combined multivariate model. Only 2.6% of
pathogenic variants could be detected with threshold 0.9
when the full BrS model was used, while the sensitivity
increased to 23% for the same threshold in the multivari-
ate model (sensitivity comparison for other thresholds is
summarised in Additional file 1: Figure S2 and Table S5).
However, the proportion of confident predictions is con-
siderably lower than for LQTS due to the smaller training
set.
Models for hypertrophic cardiomyopathy
Finally we built a prediction model for HCM based on
rare variants in MYH7, TNNT2, TNNI3 and MYBPC3.
We had two training sets available for this syndrome (see
above). After checking that the predictive models built on
each data set separately performed similarly, we merged
the training sets, resulting in 85 pathogenic and 67 benign
variants, after removing 14 duplicates. These were ran-
domly allocated into 100 training and test sets as for
LQTS.
We compared the full model with a gene model that
omitted domain effects. The full model is shown in
Figure 5, alongside the full LQTS model for compari-
son. The full model reached sensitivities of 40% and 50%
with false positive rates of 5% and 10%. The gene model
is inferior to the full model for any false positive rate
considered.
As before, we investigated merging the HCM and LQTS
models to improve predictive performance. Merging was
as described for the BrS model, except that intercepts and
scale parameters of prior odds of genes were estimated
separately for HCM and LQTS, as the HCM data set was
larger than that for BrS. The ROC curves were drawn for
each syndrome separately (see Figure 5 and Additional
file 1: Figure S2).
As for BrS, combining data across syndromes improves
predictions at low false positive rates, but it remains
that high sensitivity for HCM can only be achieved with
large false positive rates. The relatively poor performance
for the HCM model, with or without merging, may be
attributable to a less informative domain architecture for
HCM genes, and relatively more missense substitutions
and fewer radical variants in the HCM training data.
We calculated sensitivities and PPVs for the predictions
for variants in HCM genes when the combined multivari-
ate model is used. The PPV for MYH7 at threshold 0.9
is 0.994, but only 26% of pathogenic MYH7 variants are
assigned probabilities > 0.9. ForMYBPC3, no pathogenic
Figure 5 Comparison of pathogenicity prediction models for hypertrophic cardiomyopathy. Receiver operating characteristic curves for the
full HCMmodel (full model, HCM) and a simpler gene model without domain-specific prediction (gene model, HCM) are shown alongside the LQTS
classifier for comparison. As for BrS, the full HCMmodel was re-estimated in combination with the LQTS model with modest benefits at low false
positive rates. BrS, Brugada syndrome; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome.
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variant had a probability of pathogenicity > 0.9 (see
Additional file 1: Table S5). The multivariate model was
surprisingly sensitive when detecting pathogenic variants
in TNNT2: 83% of these variants had probability > 0.9,
while the PPV was 0.985 at this threshold. All PPVs for
TNNI3 were 1, although sensitivity was rather low: 34%
of pathogenic variants were identified at the 0.9 threshold.
The variability of sensitivity across HCM genes was unex-
pected and could probably be eliminated by more detailed
domain annotations.
Estimated effect sizes of predictors in the long QT
syndromemodel
Focussing on the LQTS model because of the much larger
training set available, we investigated which predictors are
the most informative, and assessed the biological plausi-
bility of estimated effect sizes (Figure 6). For all predictors
for which there was a clear prior expectation, the direc-
tions of effects are as expected; for example, the probabil-
ity that a variant is pathogenic increases with its level of
conservation.
SIFT score has a large effect on predictions (Figure 6),
while PolyPhen and Grantham each have a moderate
impact. The quadratic influence upon the pathogenic risk
is more pronounced for PolyPhen than for Grantham
when modelled jointly with other predictors, whereas
assessed individually they showed an equally strong indi-
cation of non-linearity.
The intercept for missense variants (Figure 6) is highly
negative, reflecting their greatly reduced probability to
be pathogenic relative to inframe indels and radical vari-
ants, and so substantial other evidence is required for a
missense variant to have high probability of pathogenic-
ity. The inframe intercept is much higher but somewhat
less than that for radical variants, in concordance with
previous reports [5].
The gene effects for radical variants imply that the pre-
dictions for this type of variant are confident in both
directions: variants in two major LQTS genes are classi-
fied as pathogenic, while others are assumed to be benign
in the absence of other evidence. This is consistent with
molecular mechanisms underlying LQTS caused by these
genes, for example LQTS is caused by gain of function of
SCN5A and CACNA1C, while radical variants are likely to
cause loss of function. The small number of radical vari-
ants for all LQTS genes apart from KCNQ1 and KCNH2
leads to a considerable weight being given to the prior
odds of genes for radical variants by the model fitting.
The domain effects in Figure 6 are grouped by genes
and ordered according to the sequence of domain cod-
ing segments on the genome. There is evidence of
clusters of domains with similar magnitude and direc-
tion of effect, in keeping with a previous report [5].
For example, consistent domain effects are observed for
KCNQ1 (from the Transmembrane/Linker/Pore region
and TM helical S3 domain through to the end of
the Transmembrane/Linker/Pore segment), for KCNH2
(from the N-terminus (Per-Amt-Sim) till the Transmem-
brane/Linker/Pore (TM cytoplasmic domain)) and for
SCN5A (from TM domain 3 (TM intracellular S4-S5)
until the end of TM domain 4). No prior informa-
tion about domain order was used by the model, and
this observation suggests that there is scope for better
predictions that exploit domain order. However, sim-
plifying the model by merging domains in the low-
resolution LQTSmodel reduced prediction accuracy, per-
haps because boundaries of the observed domain clus-
ters do not always coincide with the UniProt features
that we used as the basis of our mergers [5]. For exam-
ple, in KCNQ1 a boundary emerges within the Trans-
membrane/Linker/Pore region, between a TM cytoplas-
mic domain and the helical S3 domain, rather than at
the limit of the Transmembrane/Linker/Pore region. Our
unexpected observed boundaries on further investiga-
tion might lead to improved understanding and better
predictions.
Although domain effects were estimated from infor-
mation about variants in the training set alone, many
of these effects are consistent with the literature. For
example, it has been reported that variants in Transmem-
brane/Linker/Pore domains of KCNH2 are more likely to
be pathogenic than those in either the C-terminus or N-
terminus [5]. This is confirmed in Figure 6, which also
yields more detailed information about the pathogenic
risk of individual Transmembrane/Linker/Pore domains.
Model implementation and distribution
We have developed an online implementation of the
full prediction model for LQTS: APPRAISE: Assessing
Pathogenicity PRobAbility by Integrating Statistical
Evidence [34]. Scripts and materials required to replicate
these analyses are provided in the Additional files, and
are available on GitHub [35].
Discussion
We present a network of nine interrelated Bayesian
logistic regression models that discriminate between
pathogenic and benign variants in genes associated with
inherited cardiac conditions. The nine models encompass
three variant classes (radical, inframe indel and missense
substitution) for each of three syndromes (LQTS, BrS
and HCM). A feature of our models is the gene- and
domain-specific terms, which are estimated from train-
ing data specific to each syndrome. Another feature is the
sharing of some predictors across syndromes, to benefit
from improved parameter estimation by combining train-
ing data over syndromes. Our approach should be widely
applicable to other monogenic inherited conditions,
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Figure 6Magnitude of effect sizes estimated from the full LQTSmodel. A positive effect size indicates that the evidence supports
pathogenicity, whereas a negative effect size indicates evidence against pathogenicity. On the left, the effect size for each gene and domain term is
shown, with gene effects corresponding to the logarithm of the prior odds for non-radical variants in Table 1 multiplied by a scale parameter.
Domains are ordered sequentially according to genome position. The colour of the bars reflects the number of variants in the LQTS training set for
each gene or domain: magenta bars are derived from many training variants (indicating high confidence), and grey bars from few variants. The top
right panel shows the effect size for other binary variables, i.e. variant class (inframe/missense), allele frequency and conservation classes. The middle
right panel includes gene terms for radical variants, where a gene term corresponds to the logarithm of the prior odds for radical variants in Table 1
multiplied by a scale parameter and added to the effect of variant class (radical). Magenta bars imply many training variants, while grey bars indicate
few radical variants and white bars denote genes without any radical variants in the LQTS training data. The bottom right panel shows the effect size
for continuous predictors (nsSNP algorithms) as linear or quadratic functions of the predictor value. Interd., Interdomain; IQ, IQ calmodulin binding
motif, named after the first two amino acids of the motif, isoleucine (I) and glutamine (Q); L., Linker; LQTS, long QT syndrome; PAS, Per-Arnt-Sim
domain, named after homology to the Drosophila period protein (PER), the aryl hydrocarbon receptor nuclear translocator protein (ARNT) and the
Drosophila single-minded protein (SIM); PPh2, PolyPhen-2; TM, Transmembrane; Transm., Transmembrane; volt., voltage.
provided that suitable training data are available, but the
extent to which information can be shared across syn-
dromes requires careful investigation.
The output of this Bayesian approach is a posterior
probability of pathogenicity, allowing users to choose
their preferred threshold for declaring a variant to be
pathogenic. In the numerical examples here, we have
taken a probability of 0.9 as a threshold value to cal-
culate performance metrics for comparison. Other cate-
gories can also be defined by appropriately partitioning
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the probability values, for example ‘possibly pathogenic’
or ‘likely benign’ [9,30,31].
Our Bayesian framework is transparent in its assump-
tions and can be readily extended to incorporate new
lines of evidence to assess the pathogenicity of a novel
genetic variant. In particular, familial segregation of a phe-
notype with a variant provides evidence of pathogenicity
that is independent of the predictors in our models. The
LOD (logarithm of odds) score used to quantify linkage
between a variant and a trait is a likelihood ratio, and the
posterior probability can easily be recalculated in the light
of this further evidence, e.g.
Posterior odds = Prior odds × LR(predictor model)
× LR(segregation data)
This means that modest evidence for pathogenicity may
be combined with modest segregation data from a small
family to yield a confident prediction.
In practice, the probabilities reported by our models
are conservative because of the conservative prior prob-
abilities that we have employed. For example, we found
that using the cut-off P(pathogenic) > 0.9 yields a PPV
of 0.999, with sensitivity 0.76 combined over the three
most important LQTS genes (sensitivity is 0.73 for all
13 LQTS-related genes). In other words, a probability of
pathogenicity >0.9 represents a highly confident predic-
tion in favour of pathogenicity, but the price of this high
confidence is that nearly one-third of pathogenic variants
will be missed. Users of the model can choose other cut-
offs to obtain a different balance between sensitivity and
specificity.
Under what circumstances are confident, and there-
fore clinically actionable, predictions obtained? The gene
effect sizes for radical variants imply that the predictions
for novel radical variants in these genes will almost always
be confident, in keeping with our prior knowledge, and in
accordance with current clinical practice. Inframe indels
have previously been treated as radical [5], though there
are a number of polymorphisms in this class. The use
of frequency information in the model allows for confi-
dent benign predictions for this type of polymorphism.
Novel missense substitutions overall yield less confident
predictions, as expected. Nonetheless, the use of domain
information in particular allows for justifiably confident
predictions for variants in some protein domains. Strong
and concordant predictions from SIFT and PolyPhen can
also generate a relatively high probability of pathogenicity
for missense substitutions in some genes.
One aspect of our decision-making that is made explicit
in this framework is the prior probability of pathogenic-
ity. Here, we have estimated this on a gene-by-gene basis
for each syndrome. Importantly, when we compared a
series of nested models of increasing complexity, the sin-
gle largest improvement came in moving from a genome-
wide model to a gene-specific model, suggesting that this
approach, tailored for each gene and syndrome, is more
powerful than genome-wide approaches, as has been sug-
gested previously [12,13]. This suggestion can be con-
firmed as more data become available through centralised
databases and registries.
Our prior probabilities are based on prospective real-
world estimates of the yield of genetic testing, rather
than curated case series that selectively include only
robustly phenotyped cases. Nonetheless, if clinicians were
to employ genetic testing without appropriate case selec-
tion, then the priors used here would no longer be applica-
ble. However, the framework does provide an opportunity
for further refinement, in which the prior probability
could be modulated by the patient’s phenotype. For exam-
ple, the prior probability might be augmented by extreme
values of the QT interval in LQTS, by ventricular wall
thickness in HCM or by a strong family history.
The priors can also be adjusted to allow for different
testing strategies. The current priors assume that all genes
for a given syndrome are examined simultaneously, for
example, using a broad next-generation sequencing panel.
Alternatively, onemight choose to test only the three prin-
cipal LQTS genes in a first wave of testing, and test the
remaining genes only in those who are genotype negative,
as is common practice in laboratories using conventional
sequencing. Here the gene probabilities for the second
round of testing depend on the results of the first: the
probability that an observed variant in a minor LQTS
gene is pathogenic is substantially higher if this testing is
reserved for those with a clear phenotype, but no causative
variant in the three principal LQTS genes.
Having concluded that gene-specific models are pre-
ferred to genome-wide models, it is notable that the
models could nonetheless be improved by merging some
parameters between models, particularly where training
data were sparse. For example, the use of training data
from several diseases to estimate the likelihood ratio dis-
tributions for SIFT, PolyPhen, Grantham and Conserva-
tion scores, while retaining disease-specific gene priors
and domain models, improved predictions from the BrS
and HCMmodels, at least at the extremes of the distribu-
tion of outcomes.
We have arrived at the proposed Bayesian model via
model selection. We have compared the predictive per-
formance of the models making use of various subsets
of predictors. In principle, the model selection process
could be replaced by model averaging or ensemble learn-
ing. However, the number of available predictors was not
so large in our case to benefit from the variety of mod-
els included in an ensemble (frequent repetitions of a few
models would be inevitable). We observed in simulations
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that it was relatively straightforward to decide whether
a predictor should be included in the model or not: it
either had no influence on the sensitivity and specificity or
there was a consistent improvement in sensitivity or speci-
ficity. However, we might need to consider probabilistic
approaches to model selection when more predictors of
rare variant pathogenicity become available.
Training the full model for a LQTS data set required
approximately one and a half hours on a desktop computer
running the Unix CentOS operating system (four cores of
2.83 GHz each and 3.6 GB RAM). The time of training a
new model looks linear for the number of variants in the
data set. Extra care has to be taken for memory, because as
the data set increases the number of estimated parameters
whose values are stored throughout the simulation can
also increase; for example, there can be more genes and
domains to take into account. It seems that our modelling
approach could be applied to data sets with a few thousand
rare variants, if more powerful computational means are
employed and additional optimisations for memory use
are implemented.
This approach is limited in that variants are assessed
individually for a likely causative role in monogenic dis-
ease. There is no consideration of oligogenic inheritance
or the role of modifier variants. The severity of disease
associated with any given variant is also not assessed. Rare
variant burdens in cases and controls were not obtained
using a uniform sequencing strategy, which could influ-
ence estimated prior odds. In our HCM model, we used
the generic PolyPhen classifier, rather than the disease-
specific PolyPhen HCM [12], because the PolyPhen HCM
predictor was optimised using a small training data set
that is incorporated into our HCM training data.
Conclusions
Disease-specific Bayesian models provide a robust, accu-
rate and transparent framework to integrate multiple
sources of evidence available for the interpretation of
novel variants identified during gene sequencing. The
models presented here are immediately applicable to clin-
ical diagnostics for inherited cardiac conditions, and pro-
vide important lessons for the development of predictors
for other clinically important diseases.
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